INTRODUCTION
Ovarian cancer is the leading cause of death from gynecological cancers in developed countries. The majority of ovarian cancer patients are diagnosed with an advanced stage of the disease, and as such they typically have a 5-year survival rate lower than 30% [1] . For the majority of women, cytotoxic chemotherapeutics have limited efficacy. Therefore, there is an urgent need for alternative anticancer agents that have the potential to control tumor growth, improve the quality of life, and increase the longevity of patients.
A number of targeted anticancer drugs have been studied; among these drugs are small molecule inhibitors of receptor tyrosine kinases. A subset of cancer cells is dependent on the over activation of epidermal growth factor receptor proteins including EGFR and Her-2. Therefore, an inhibitor that specifically blocks these receptors may have clinical activity. Specific inhibitors of EGFR and Her-2 including gefitinib, erlotinib, lapatinib, and a monoclonal antibody Herceptin have been approved by the FDA to treat different types of cancers that include breast cancer, colon cancer and non-small cell lung cancer, NSCLC [2, 3] .
The EGFR and Her-2 inhibitors as a monotherapy show minimal clinical benefit in ovarian cancer trails [4, 5] . The lack of clinical efficacy of these inhibitors is perhaps due to activation of multiple receptor tyrosine kinases and the activation of several down stream signaling proteins. In this study, we explore the possibility that targeting of multiple receptor tyrosine kinases will lead to greater effects on tumor growth potential.
Some advanced ovarian cancer cells have been shown to possess high levels of the receptors EGFR and Her-2 [6] . It is the activation of these receptors that may promote the growth of malignant cells, and the over expression of these receptors has been associated with a poor prognosis and invasive phenotypic changes [7, 8] . There is evidence to suggest that EGFR/Her-2 expressing malignant cells may not be sensitive to the EGFFR and Her-2 inhibitors as ovarian cancer cells are able to use alternate a receptor tyrosine kinase for growth promotion [9] . The c-Met is also a receptor tyrosine kinase, which has elevated levels in ovarian cancer cells [10] . The c-Met receptors are activated when they are bound by the hepatocyte growth factor, HGF, which is elevated in the ascitic fluid of women with advanced stages of ovarian cancer [11] . The EGFR, Her-2 and c-Met receptors share common downstream signaling molecules that can promote cell survival, motility, and invasion and cross-communication between these three receptors may promote cancer progression and resistance to therapy [12] . Thus, c-Met could be an additional potential target for cancer treatment and raises the strategic possibility of combined targets of receptor tyrosine kinases concurrently.
Candidate molecules for such combined strategies are canertinib and PHA665752. Canertinib, also known as CI-1033, is an irreversible inhibitor of receptor tyrosine kinases, binding to the ATP-binding site. It has shown potent effects against several cancer cell lines targeting EGFR and Her-2. Clinical trials of canertinib have been conducted against a number of tumor types, including breast cancer [13] , NSCLC [3] , and advanced ovarian cancer [5] . However, canertinib alone showed modest activities in clinical studies with ovarian cancer patients [5] . PHA665752 is a reversible inhibitor of c-Met, which at nano-molar concentrations has shown in vivo anti-tumor activity [14] .
Advanced ovarian cancer patients often have ascitic fluid in the abdominal cavity. In the fluid, ovarian malignant cells form 3D structures; these microscopic clusters and aggregates are a major source of secondary growth potential [15, 16] . These clusters and aggregates then deposit on the peritoneal lining and the surface of internal organs to continue their growth. Therefore, it is appropriate to use cell clusters and aggregates as an in vitro cell model to replicate the behavior of ovarian cancer cells. We hypothesized that floating cell clusters and aggregates ovarian cancer cells may use the concurrent activation of EGFR, Her-2 and c-Met to sustain growth and cell survival. Combined inhibition of these receptors will produce a greater anti-growth effect in ovarian cancer cells. The aim of the present study was to test the effect of such combined inhibitors on 3D cell cultures of two ovarian cancer cell lines, OVCAR-5-and SKOV-3.
METHODS
The human ovarian adenocarcinoma cell lines, Apotome software, Carl Zeiss, Oberkochen, Germany).
Immunoblotting Analysis
Cell clusters and aggregates were harvested by centrifugation at 400g for 5 min, and the cell pellets were lyzed in cold RIPA buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM EDTA, The protein bands were visualized and a densitometry analysis was performed using 
Statistical Analysis
Statistical analysis of data was carried out using 
RESULTS

Morphology and Expression EGFR, Her-2, and c-Met
OVCAR-5 cells formed small cell clusters when cultured on a non-adherent surface (Fig. 1a) . In contrast, SKOV-3 cells formed large cellular aggregates with dense multicellular structures (Fig. 1b) . To determine the presence of cell receptors, we immunofluorescently labeled OVCAR-5 clusters and SKOV-3 cellular aggregates. OVCAR-5 clusters were EGFR (Fig. 1c ) and c-Met positive (Fig. 1g ), but had low expression of Her-2 ( Fig. 1e) . SKOV-3 aggregates were EGFR, Her-2 and c-Met positive (Fig. 1d, f, h ).
EGF and HGF Increase the Growth of OVCAR-5 Clusters and SKOV-3 Aggregates
We chose two concentrations of the growth factor EGF and HGF; a physiological concentration (0.2 ng/ml) that approximates to that present in ovarian cancer patients, and a concentration that is commonly used in in vitro studies (20 ng/ml). The growth of OVCAR-5 cell clusters was not increased in the presence of the physiological concentration of growth factor (p = 0.4076). However, the higher 
Canertinib and PHA665752 Alone Inhibit the Growth of Clusters and Aggregates
We next investigated whether growth of cell clusters and aggregates could be inhibited by the (Fig. 2c,  d ). The inhibitor was very potent against SKOV-3 cell aggregates (p[0.0001) (Fig. 2e, f) . Interestingly, the inhibition of canertinib was growth factor independent.
We then examined the effect of PHA665752 on growth. PHA665752 inhibited growth of OVCAR-5 clusters in a concentration-dependent manner (p[0.0001) (Fig. 3a, b) . Its effect on SKOV-3 aggregates was less pronounced, but there still was a decrease in growth (p[0.05) (Fig. 3c, d) . Interestingly, growth inhibition by PHA665752 in the presence of low and high concentration mixtures of growth factors was not statistically different (data not shown).
Effect of a Combination of Both Canertinib and PHA665752
We investigated the effects of a combination of canertinib and PHA665752 at respective concentrations of 3 lM and 1 lM, which were the lowest effective doses from the single drug treatment experiments. The combination of Fig. 4a ) and SKOV-3 (Fig. 4b) cells.
Growth was more reduced with the inhibitor combination, than with the respective single inhibitor alone, in both OVCAR-5 clusters (Fig. 4c ) and SKOV-3 aggregates (Fig. 4d) (p[0.0001) in the presence of 0.2 ng/ml GF. Similar patterns of inhibition were obtained with 20 ng/ml GF for OVCAR-5 and SKOV-3 (Fig. 5 ).
Canertinib and PHA665752 Reduce Expression of EGFR, Her-2 c-Met, and Their Downstream Signaling Molecules in OVCAR-5 Cell Clusters
Both single and combined applications of the inhibitors significantly reduced p-EGFR (Fig. 6a,  b) in OVCAR-5 cell clusters in the presence of 0.2 ng/ml GF. However, the total expression of EGFR was only reduced in canertinib-treated cells (Fig. 6c) . Both c-Met and phosphorylated-c-Met proteins were significantly reduced with a single treatment of PHA665752, and this was further decreased with the combination (Fig. 6a, d, e) . The combination of inhibitors reduced the total expression of Akt (Fig. 6g) and there was a tendency for reduction of Akt phosphorylation (Fig. 6f) . The phosphorylation of Erk was reduced in a single treatment alone, but there was greater reduction of p-Erk in the combined inhibitors (Fig. 6h) . The total expression of Erk (Fig. 6i) All experiments were independently performed at least three times with triplicates. Data analyzed using one-way ANOVA. Data considered statistically significant are indicated as p\0.05 (*), p\0.01 (**), p\0.001 (***), and p\0.0001 (****) when compared to the control or the other doses (Fig. 8a) , while the application of PHA665752 alone did not reduce p-EGFR. The combination treatment gave a similar result to canertinib alone (Fig. 8b) . The total expression of EGFR itself was also reduced with canertinib, and with the combination treatment (Fig. 8c ).
Phosphorylation and total expression of Her-2 was significantly reduced in both the canertinib and the combination treatment (Fig. 8d, e) . Canertinib alone and the combination significantly reduced the phosphorylation of c-Met (Fig. 8f) . The single inhibitor treatment reduced the total expression of c-Met, but a greater reduction was observed in the combination (Fig. 8g) . The reduction of p-Akt, and p-Erk were also notable in the combination treatment. The total expression of Erk was slightly reduced in the canertinib and combination treatment. Similar results were obtained when cells were activated with 20 ng/ ml combined GF (Fig. 9) .
DISCUSSION
A subset of advanced ovarian cancer cells have previously been shown to express high levels of receptor tyrosine kinases that are associated with rapid growth and proliferation. EGFR and Her-2 were upregulated in 53% and 25%
of patients with advanced ovarian cancers, respectively, and these were thought to be associated with resistance to chemotherapy and a poor prognosis [8] . and this rationale has been described by other studies [2, 17, 18] . Co-activation of multiple receptor tyrosine kinases may reduce the Consistent with previous reports, we found that the OVCAR-5 cells formed small clusters while the SKOV-3 cells formed aggregates [23, 24] . We also show that OVCAR-5 cell clusters express high levels of EGFR and c-Met, but low levels of Her-2 and that the SKOV-3 aggregates express high levels of all three receptors. These observations are consistent with a previous study [25] . In previous studies, a variety of EGF and HGF concentrations have been used ranging from 10 to 200 ng/ml [26, 27] . However, these concentrations are not physiologically relevant in women with advanced ovarian cancer [28] . We show that a concentration of 0.2 ng/ml, which is a more In our study, we demonstrate that the combined inhibitors (using the lowest effective EGFR-mutation mediated erlotinib-resistant lung cancer cells [42] .
In clinical trials, the combination of cytotoxic agents with small molecule receptor tyrosine kinase inhibitors or monoclonal antibodies has been also investigated in ovarian and other cancers. 
